To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

NCT05814523 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Refractory Status Epilepticus

Interventions

DRUG: Ganaxolone
DRUG: Placebo
DRUG: Standard of care

Sponsor

Marinus Pharmaceuticals